ArticleAntimicrobial agents and chemotherapy2026
Colonization with extended-spectrum and AmpC β-lactamase-producing Enterobacterales and bacteremia risk in patients with acute leukemia who receive induction chemotherapy without fluoroquinolone prophylaxis.
Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Neutropenic patients colonized with extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) frequently develop ESBL-E bacteremia while receiving fluoroquinolone prophylaxis. However, the impact of colonization with ESBL-E and AmpC β-lactamase-producing Enterobacterales (AmpC-E) in neutropenic patients who do not receive fluoroquinolone prophylaxis is unclear. To investigate this, we conducted a prospective study of patients with acute leukemia or myelodysplastic syndrome (MDS) receiving induction chemotherapy without antibacterial prophylaxis between November 2015 and January 2020. Stool or perianal swab specimens were collected from study participants within 5 days of initiating chemotherapy and underwent culture for ESBL-E and AmpC-E. Isolated organisms were identified and subjected to antimicrobial susceptibility testing and whole-genome sequencing. Bacteremia risk during neutropenia was compared between ESBL-E-colonized, AmpC-E-colonized, and non-colonized patients. We enrolled 159 patients, of whom 15 (9%) were colonized with ESBL-E and 17 (11%) with AmpC-E. Fourteen (93%) of 15 colonizing ESBL-E isolates were cefepime resistant, compared to 2 (12%) of 17 AmpC-E isolates. Three (20%) of 15 ESBL-E-colonized patients developed ESBL-E bacteremia (colonizing and bloodstream isolates were genetically identical for each patient), compared to 1 (1%) of 144 patients without ESBL-E colonization (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.